Acute Ketamine Infusion in Rat Does Not Affect In Vivo [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5

Detecting changes in metabotropic glutamate receptor 5 (mGluR5) availability through molecular imaging with the positron emission tomography (PET) tracer [11C]ABP688 is valuable for studying dysfunctional glutamate transmission associated with neuropsychiatric disorders. Using an infusion protocol in rats, we visualized the acute effect of subanesthetic doses of ketamine on mGluR5 in rat brain. Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist known to increase glutamate release. Imaging was performed with a high-affinity PET ligand [11C]ABP688, a negative allosteric modulator of mGluR5. Binding did not change significantly from baseline to ketamine in any region, thereby confirming previous literature with other NMDA receptor antagonists in rodents. Hence, in rats, we could not reproduce the findings in a human setup showing significant decreases in the [11C]ABP688 binding after a ketamine bolus followed by ketamine infusion. Species differences may have contributed to the different findings in the present study of rats. In conclusion, we could not confirm in rats that endogenous glutamate increases by ketamine infusion are reflected in [11C]ABP688 binding decreases as was previously shown for humans.

[1]  J. Démonet,et al.  Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience , 2019, Front. Med..

[2]  K. Behar,et al.  Glutaminase activity in GLS1 Het mouse brain compared to putative pharmacological inhibition by ebselen using ex vivo MRS , 2019, Neurochemistry International.

[3]  S. Mingote,et al.  Molecular Imaging of mGluR5 Availability with [11C]ABP68 in Glutaminase Heterozygous Mice , 2018, Cellular and Molecular Neurobiology.

[4]  Yiyun Huang,et al.  In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Steven Staelens,et al.  Fast and Accurate Rat Head Motion Tracking With Point Sources for Awake Brain PET , 2017, IEEE Transactions on Medical Imaging.

[6]  R. Parsey,et al.  Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression , 2017, Molecular Psychiatry.

[7]  Steven Staelens,et al.  Markerless rat head motion tracking using structured light for brain PET imaging of unrestrained awake small animals , 2017, Physics in medicine and biology.

[8]  K. Wernecke,et al.  Influence of Volatile Anesthesia on the Release of Glutamate and other Amino Acids in the Nucleus Accumbens in a Rat Model of Alcohol Withdrawal: A Pilot Study , 2017, PloS one.

[9]  A. Bauer,et al.  Circadian variation of metabotropic glutamate receptor 5 availability in the rat brain , 2016, Journal of sleep research.

[10]  Phillip E. Vlisides,et al.  Ketamine: 50 Years of Modulating the Mind , 2016, Front. Hum. Neurosci..

[11]  J. Mann,et al.  Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [11C]ABP688 , 2015, Translational Psychiatry.

[12]  R. Parsey,et al.  In Vivo Ketamine-Induced Changes in [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5 , 2015, Biological Psychiatry.

[13]  V. Treyer,et al.  Metabotropic glutamate receptor 5 binding in patients with obsessive-compulsive disorder. , 2014, The international journal of neuropsychopharmacology.

[14]  Steven Staelens,et al.  The [18F]FDG μPET Readout of a Brain Activation Model to Evaluate the Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator JNJ-42153605 , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[15]  Mark E. Schmidt,et al.  N-Acetylcysteine– and MK-801–Induced Changes in Glutamate Levels Do Not Affect In Vivo Binding of Metabotropic Glutamate 5 Receptor Radioligand 11C-ABP688 in Rat Brain , 2013, The Journal of Nuclear Medicine.

[16]  Yiyun Huang,et al.  Awake Nonhuman Primate Brain PET Imaging with Minimal Head Restraint: Evaluation of GABAA-Benzodiazepine Binding with 11C-Flumazenil in Awake and Anesthetized Animals , 2013, The Journal of Nuclear Medicine.

[17]  Yiyun Huang,et al.  Studies of the metabotropic glutamate receptor 5 radioligand [11C]ABP688 with N‐acetylcysteine challenge in rhesus monkeys , 2013, Synapse.

[18]  H. William Strauss,et al.  Recent Advances in the Molecular Imaging of Programmed Cell Death: Part II—Non–Probe-Based MRI, Ultrasound, and Optical Clinical Imaging Techniques , 2013, The Journal of Nuclear Medicine.

[19]  A. Aliaga,et al.  Test‐retest stability of cerebral mGluR5 quantification using [11C]ABP688 and positron emission tomography in rats , 2012, Synapse.

[20]  X. Langlois,et al.  Patterns of Brain Glucose Metabolism Induced by Phosphodiesterase 10A Inhibitors in the Mouse: A Potential Translational Biomarker , 2011, Journal of Pharmacology and Experimental Therapeutics.

[21]  Gregor Hasler,et al.  Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. , 2011, The American journal of psychiatry.

[22]  X. Langlois,et al.  Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist , 2011, Psychopharmacology.

[23]  Christine DeLorenzo,et al.  In vivo positron emission tomography imaging with [11C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  T. Patterson,et al.  Potential neurotoxicity of ketamine in the developing rat brain. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  H. Hemmings,et al.  Volatile Anesthetic Effects on Glutamate versus GABA Release from Isolated Rat Cortical Nerve Terminals: Basal Release , 2006, Journal of Pharmacology and Experimental Therapeutics.

[26]  Simon R. Cherry,et al.  Development and evaluation of an automated atlas-based image analysis method for microPET studies of the rat brain , 2003, NeuroImage.

[27]  H. Hemmings,et al.  Effects of Isoflurane and Propofol on Glutamate and GABA Transporters in Isolated Cortical Nerve Terminals , 2003, Anesthesiology.

[28]  Jeffrey A Lieberman,et al.  Effects of Ketamine, MK-801, and Amphetamine on Regional Brain 2-Deoxyglucose Uptake in Freely Moving Mice , 2000, Neuropsychopharmacology.

[29]  R. Mailman,et al.  Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation , 1998, Brain Research.

[30]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[31]  A. Young,et al.  Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5 , 1995, Neuropharmacology.

[32]  I. Langmoen,et al.  The effect of the volatile anesthetic isoflurane on Ca2+-dependent glutamate release from rat cerebral cortex , 1994, Brain Research.

[33]  M. Cohen,et al.  Distribution in the Brain and Metabolism of Ketamine in the Rat after Intravenous Administration , 1973, Anesthesiology.

[34]  M Slifstein,et al.  Imaging glutamate in schizophrenia: review of findings and implications for drug discovery , 2014, Molecular Psychiatry.

[35]  J. Clements,et al.  Pharmacokinetics and analgesic effect of ketamine in man. , 1981, British journal of anaesthesia.